Rituximab The First Monoclonal Antibody Approved for the Treatment of Lymphoma

Publisher： Bentham Science Publishers

E-ISSN： 1873-4316|1|1|1-9

ISSN： 1389-2010

Source： Current Pharmaceutical Biotechnology, Vol.1, Iss.1, 2000-01, pp. : 1-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rituximab and other emerging monoclonal antibody therapies for lymphoma

By Tobinai Kensei  

Expert Opinion on Emerging Drugs, Vol. 7, Iss. 2, 2002-10 ,pp. : 289-302

Informa Healthcare

Access to resources Recommend Favorite

An Evaluation of the Cost-Effectiveness of Rituximab in Combination with Chemotherapy for the First-Line Treatment of Follicular Non-Hodgkin's Lymphoma in the UK

By Ray Joshua A.   Carr Emma   Lewis Gavin   Marcus Robert  

Value in Health, Vol. 13, Iss. 4, 2010-06 ,pp. : 346-357

Blackwell Publishing

Access to resources Recommend Favorite

Exposure-Effect Population Model of Inolimomab, a Monoclonal Antibody Administered in First-Line Treatment for Acute Graft-Versus-Host Disease

By Dartois Céline   Freyer Gilles   Michallet Mauricette  

Clinical Pharmacokinetics, Vol. 46, Iss. 5, 2007-01 ,pp. : 417-432

Adis International

Access to resources Recommend Favorite

Monoclonal Antibodies in the Treatment of Non-Hodgkin's Lymphoma

By Fanale Michelle A.   Younes Anas  

Drugs, Vol. 67, Iss. 3, 2007-01 ,pp. : 333-350

Adis International

Access to resources Recommend Favorite

Rituximab + CHOP: first-line therapy in B-cell lymphoma

By  

Inpharma, Vol. 1, Iss. 1323, 2002-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite